Melitracen

DB13384InvestigationalSmall molecule

Melitracen is a thioxanthene neuroleptic indicated in the treatment of anxiety, depression, and asthenia. A medication used to treat anxiety, depression, and unusual weakness or tiredness.

Mechanism: Pharmacologically active on Sodium-dependent noradrenaline transporter and Sodium-dependent serotonin transporter
Curator reviewed
Formula / weight: C₂₁H₂₅N · 291.438 g/mol (avg)

Resolves to

Compound

UNIIQ7T0Y1109ZCAS5118-29-6ChEMBLCHEMBL110094ChEBI135214

Clinical / RWD

RxNorm446248ATCN06AA14ATCN06CA02

Structure

InChIKeyGWWLWDURRGNSRS-UHFFFAOYSA-NSMILESCN(C)CCC=C1C2=CC=CC=C2C(C)(C)C2=CC=CC=C12

Targets

P23975SLC6A2P31645SLC6A4

What you can answer from here — as of July 18, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1,353Drug interactionsStructured to mechanism, not free text

14Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

11ContraindicationsEach with its own population and attribute set

10Marketed productsAcross 5 countries and 6 labellers

2ATC codesIncluding every combination product, plus 13 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Melitracen, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In